Aiden Tech Secures $300M Series B Funding to Advance Healthcare Equity Through AI-Powered DRG/DIP Solutions

VCBeat (WeChat: vcbeat) learned at the earliest opportunity that, recently,AI Healthcare Big Data Company Aideng Technology Announces Completion ofRMB 200 millionBround of financing, led by Zhongding Capital, Legendstar Capital,Co-participated by Innovation Works. This round of financing will be used for the continuous R&D and iteration of Aideng Technology's products and technologies, the establishment of a sales team, and related market expansion. Previously, the company had received investment led by Innovation Works.Series A Financing.

Aideng Technology focuses on in-depth big data mining and artificial intelligence applications within the healthcare industry, leveraging “artificial intelligence,” “disease classification,” and “medical record quality control” as its entry points. The company provides comprehensive SaaS-based DRG/DIP solutions to nearly 4,000 secondary and tertiary medical institutions, covering services such as medical service efficiency evaluation, health insurance fund accounting, cost accounting, performance allocation, clinical pathway analysis, and discipline construction. Since 2016, the company has been building an “AI-driven Disease Classification Knowledge Graph.” After nearly six years of refinement, it has become one of the most widely adopted AI tools for disease classification in terms of market share.

The National Healthcare Security Administration’s “Three-Year Action Plan for DRG/DIP Payment Method Reform” establishes detailed quantitative requirements for pooling areas, medical institutions, disease coverage, and healthcare fund participation. While accelerating the comprehensive rollout of DRG/DIP payment methods, it has also catalyzed the digital transformation of hospitals. Over 300 pooling areas and tens of thousands of hospitals across China will implement relevant information systems, thereby accelerating the development of the medical IT industry. The market for DRG/DIP information systems is projected to exceed RMB 10 billion over the next three years.

Behind these policies lies the issue of China’s total health expenditure growing at a rate disproportionate to its GDP. Containing unreasonable growth in medical costs, standardizing clinical practices, and promoting the efficient allocation and utilization of healthcare resources have become key objectives for the high-quality development of public hospitals. The implementation of healthcare reform policies has incentivized medical institutions to proactively control costs. Hospitals are actively advancing the adoption of Diagnosis-Related Groups (DRG) and Big Data Diagnosis-Intervention Packet (DIP) payment systems, generating strong intrinsic demand for cost containment and efficiency improvement, cost management, and performance evaluation. The expansion of DRG/DIP payment models and their coverage helps enhance the equity of health insurance payments, better achieve universal health coverage, and realize a win-win outcome for healthcare providers, insurers, and patients.

As a leading enterprise serving hospitals in China, Aideng Technology provides SaaS-based services with 100% coverage of DRG/DIP pilot payment regions, achieving superior advantages in market reach and delivery speed. It offers users functionality and experience far surpassing those of traditional on-premise systems. By adopting product design principles centered on data centralization, indicator standardization, and business process optimization, Aideng delivers a unified hospital-wide DRG & DIP medical insurance collaboration management platform that meets the needs of medical insurance payment and multi-departmental collaborative workflows.

Zhu Wei, CEO of Aideng Technology and a former physician, stated that the DRG payment reform is the most significant event in China’s healthcare industry over the past 70 years. Its core objective is to curb overtreatment and enhance medical efficiency, ultimately addressing the issue of “equity” in healthcare. The impact of the separation of prescribing from dispensing is expected to last for 20–30 years, which will disrupt underlying investment valuation logic and have a profound effect on investors. It is hoped that more capital will pay attention to the development of healthcare reform, clarify the relationship between overtreatment and medical efficiency, and invest in value-based healthcare and healthcare equity.

Zhongding CapitalIt indicates that healthcare payment reform is a redistribution of interests, balancing efficiency and equity to achieve the national governance goals of comprehensive health and common prosperity. Aden Technology remains true to its original mission, continuously investing in AI technology to evaluate and improve medical efficiency, serving the high-quality development of public hospitals, and achieving effective integration of finance and operations—this aligns precisely with the investment philosophy of Zhongding Capital.

Lu Gang, Partner at LegendstarStatement: We have been following Aideng Technology since 2016, witnessing the continuous progress of China’s healthcare payment reform as well as Aideng’s rapid growth from a team of five to 300 employees. China’s DRG system is tasked with driving two major transformations: digitalization and intelligentization. Aideng’s SaaS-based architecture combined with AI solutions is precisely designed to meet the demands of these two transformations. As one of the leading companies in the DRG field, Aideng serves as a litmus test for our healthcare investments in the value-based care sector, contributing to the realization of the “Healthy China” initiative.

Kai-Fu Lee, Sinovation VenturesStatement: Aideng Technology is one of the key portfolio companies in which Innovation Works has invested in the fields of medical AI and data. The company skillfully leverages its technology and products to assist healthcare institutions, regulatory authorities, the insurance industry, and pharmaceutical and medical device enterprises in evaluating the commercial value of medical services. It also provides efficiency optimization recommendations from multiple perspectives, including clinical practice, operational management, and supply chain, ultimately enhancing the cost-effectiveness of healthcare services. Led by CEO Mr. Zhu Wei, the team brings diverse expertise from computing, health economics, clinical medicine, and the pharmaceutical industry. Its unique product model has enabled rapid adoption by thousands of large and medium-sized healthcare institutions, making it an indispensable infrastructure for developing “value-based healthcare.” We eagerly anticipate Aideng’s future growth!

Innovation Works' Yang XiaolongAideng Technology is a data science enterprise serving the healthcare industry. By leveraging tools such as privacy-preserving computation, AI, and big data, it assesses the efficiency and value of medical services from both commercial and social resource perspectives. The company integrates multidisciplinary knowledge—including health economics, clinical medicine, and pharmacoeconomics—into SaaS offerings, providing evidence-based support for improving healthcare institution operations, planning commercial strategies for pharmaceutical technology innovation, pricing health insurance products, and formulating regulatory policies. We believe that medical value assessment is foundational to healthcare payment reform, value-based care, and healthcare equity, with the potential to drive industry transformation and contribute to national and societal well-being. Comparable in strategic importance to areas such as pharmacy benefits and digital life sciences, Aideng Technology represents one of Innovation Works’ core platform-level investments in the healthcare sector.